Management of Pulmonary Embolism in Patients Receiving Lenvatinib
Initiate therapeutic anticoagulation immediately with LMWH or fondaparinux, transition to a NOAC (apixaban, dabigatran, edoxaban, or rivaroxaban) for long-term therapy, and continue anticoagulation indefinitely given the active malignancy. 1
Initial Anticoagulation Strategy
When PE is diagnosed in a lenvatinib-treated patient, begin anticoagulation without delay while confirming the diagnosis. The 2019 ESC guidelines prioritize LMWH or fondaparinux over unfractionated heparin for parenteral anticoagulation in hemodynamically stable patients 1. This is particularly relevant for cancer patients on lenvatinib, as LMWH has demonstrated superior efficacy compared to vitamin K antagonists in this population.
Risk Stratification Determines Intensity
- High-risk PE (hemodynamic instability): Administer systemic thrombolytic therapy immediately; if contraindicated or failed, consider surgical embolectomy or catheter-directed treatment 1
- Intermediate-risk PE: Therapeutic anticoagulation with close monitoring; reserve rescue thrombolysis for hemodynamic deterioration 1
- Low-risk PE: Standard therapeutic anticoagulation 1
Long-Term Anticoagulation in Cancer Patients
For patients with active malignancy (which includes those on lenvatinib therapy), the evidence strongly supports specific approaches:
The 2009 ESMO guidelines established that LMWH at 75-80% of initial dose (150 U/kg once daily) for 6 months is more effective and safer than vitamin K antagonists in cancer patients 2. However, the 2019 ESC guidelines updated this recommendation to include NOACs as acceptable alternatives 1.
Preferred Long-Term Options:
- NOACs (edoxaban or rivaroxaban): Now recommended as acceptable alternatives to LMWH in cancer-associated VTE 1
- LMWH: Continue at reduced dose (150 U/kg once daily) if NOACs are not suitable 2
Critical caveat: The lenvatinib FDA label notes that pulmonary embolism occurred in 3% of patients (including fatal cases) in clinical trials 3. This underscores that lenvatinib itself is a thrombogenic agent, making indefinite anticoagulation essential.
Duration of Therapy
Continue anticoagulation indefinitely as long as the patient has active malignant disease 2, 1. For patients on lenvatinib:
- Active cancer treatment = active malignant disease
- Do not discontinue anticoagulation at 3 months
- Reassess only if cancer is definitively cured and lenvatinib is permanently discontinued 1
Management of Lenvatinib During PE Treatment
Do not automatically discontinue lenvatinib unless:
- Bleeding risk becomes prohibitive
- Patient requires systemic thrombolysis (assess risk-benefit carefully)
- Recurrent VTE occurs despite adequate anticoagulation
Monitoring Considerations:
The lenvatinib label warns of multiple complications that interact with PE management 3:
- Hypertension (73% of patients): Aggressive blood pressure control is essential as uncontrolled hypertension increases bleeding risk on anticoagulation
- Proteinuria (34% of patients): Monitor renal function closely as this affects NOAC dosing
- Hemorrhagic events (documented in clinical trials): Increases bleeding risk with anticoagulation
Dose reduction of lenvatinib should be considered if the patient experiences significant toxicities that compound bleeding risk (severe hypertension, significant proteinuria, thrombocytopenia) 3.
Recurrent VTE on Anticoagulation
If PE recurs despite therapeutic anticoagulation 2:
- Verify adequate anticoagulation: Check anti-Xa levels for LMWH or NOAC levels
- Assess for cancer progression: Worsening malignancy increases VTE risk
- Escalate therapy:
- Switch from reduced-dose LMWH to full-dose (200 U/kg once daily)
- If on NOAC, switch to full-dose LMWH
- Consider IVC filter only if anticoagulation is absolutely contraindicated 1
Special Situations
Severe Renal Impairment
Lenvatinib increases risk of renal dysfunction 3. If creatinine clearance falls below 30 mL/min:
- Avoid NOACs 1
- Use LMWH with anti-Xa monitoring or switch to UFH with aPTT monitoring
- Consider lenvatinib dose reduction per FDA label 3
Bleeding Complications
If major bleeding occurs:
- Hold anticoagulation temporarily
- Manage bleeding source
- Consider IVC filter placement if bleeding is prolonged and PE risk remains high 1
- Resume anticoagulation as soon as bleeding is controlled
Key Pitfalls to Avoid
- Do not use vitamin K antagonists as first-line therapy in cancer patients—they are inferior to LMWH and NOACs 2, 1
- Do not discontinue anticoagulation at 3 months in patients with ongoing cancer treatment 2, 1
- Do not routinely place IVC filters—they are reserved for absolute contraindications to anticoagulation or recurrent PE despite adequate therapy 1
- Do not ignore lenvatinib-related complications (hypertension, proteinuria) that increase bleeding risk on anticoagulation 3